phosphodiesterase‎

phosphodiesterase‎
Name	Phosphodiesterase
Ec number	3.1.4.-
Substrates	cyclic nucleotides
Products	5'-nucleotide
Cofactors	metal ions

phosphodiesterase‎ Phosphodiesterases are enzymes that hydrolyze cyclic nucleotide phosphodiester bonds, controlling intracellular signaling mediated by cyclic adenosine monophosphate and cyclic guanosine monophosphate; they are studied across biochemistry, pharmacology, and clinical medicine. Major investigations of these enzymes intersect research institutions such as National Institutes of Health, Harvard University, Max Planck Society, and clinical centers like Mayo Clinic and Johns Hopkins Hospital, with implications for fields represented by Nobel Prize laureates and translational programs at Wellcome Trust.

Function and Catalytic Mechanism

PDEs catalyze hydrolysis of cyclic nucleotides via conserved active-site residues coordinating divalent metal ions, a mechanism elucidated by groups at Massachusetts Institute of Technology, Stanford University, University of Cambridge, and structural teams at the European Molecular Biology Laboratory; mechanistic studies cite methodologies from laboratories affiliated with Royal Society fellows and collaborators from Cold Spring Harbor Laboratory, Salk Institute, California Institute of Technology and University of Oxford. Enzymatic turnover follows nucleophilic attack on the phosphorus atom, stabilized by metal ions such as magnesium or zinc, with kinetic models developed in association with researchers from Imperial College London, ETH Zurich, University of Tokyo and Peking University. Mutagenesis experiments reported by investigators at Columbia University, Yale University, University of Pennsylvania, and University of California, San Francisco mapped catalytic residues and allosteric sites, linking structural data from the Protein Data Bank and computational analyses used by teams at University of California, Berkeley and University of Michigan.

Classification and Isoforms

The PDE superfamily is divided into multiple families (PDE1–PDE11) based on sequence homology and regulatory domains, a taxonomy refined by consortia including scientists from National Academy of Sciences, Howard Hughes Medical Institute, European Research Council grantees, and investigators at Karolinska Institutet, McGill University, University of Toronto and Université Paris-Saclay. Individual isoforms such as those encoded by genes studied at Johns Hopkins University School of Medicine, University of Edinburgh, Seoul National University, and Monash University show tissue-specific expression patterns identified in transcriptomic datasets from projects affiliated with Wellcome Sanger Institute and Broad Institute. Comparative genomics work involving teams at University of Cambridge and Max Planck Institute for Evolutionary Anthropology traced PDE evolution across model organisms used in laboratories at The Rockefeller University, University of Zurich, Wageningen University, and University of Melbourne.

Regulation and Cellular Localization

Regulatory control of PDEs involves phosphorylation, binding partners, and subcellular targeting investigated by labs at Duke University School of Medicine, Vanderbilt University, University of Texas Southwestern Medical Center, and The Francis Crick Institute. Compartmentalization with scaffold proteins and anchoring complexes has been characterized in studies linked to National Heart, Lung, and Blood Institute, University College London, King's College London, and Mount Sinai Hospital. Post-translational modification pathways implicate kinases and phosphatases researched at La Jolla Institute for Immunology, Fred Hutchinson Cancer Center, Ragon Institute, and regulatory networks mapped in collaborations with European Molecular Biology Organization members.

Physiological Roles and Pathophysiology

PDEs contribute to cardiac contractility, vascular tone, neuronal signaling, and immune cell function, with clinical correlations explored at Cleveland Clinic, Royal Brompton Hospital, Toronto General Hospital, and research consortia funded by Bill & Melinda Gates Foundation and European Commission. Dysregulation has been implicated in heart failure, pulmonary hypertension, erectile dysfunction, depression, and neurodegeneration in patient cohorts studied at Mayo Clinic, Massachusetts General Hospital, Karolinska University Hospital, and multicenter trials involving World Health Organization networks. Genetic variants and disease associations have been reported by consortia including investigators from UK Biobank, All of Us Research Program, Framingham Heart Study, and population genetics groups at Wellcome Sanger Institute.

Pharmacology and Therapeutic Targeting

PDE inhibitors such as sildenafil, tadalafil, and roflumilast were developed through collaborations between pharmaceutical companies and academic centers including Pfizer, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, and translational research hubs at UCSF Medical Center and Children's Hospital Boston. Clinical trials coordinated by teams at Food and Drug Administration, European Medicines Agency, National Institutes of Health Clinical Center, and major hospitals assessed efficacy and safety in indications spanning cardiology, pulmonology, urology, and neurology. Drug discovery efforts leveraging high-throughput screening platforms at Genentech, Novartis Institutes for BioMedical Research, Roche, and university spinouts from Imperial College London used structure-guided design informed by groups at University of Cambridge and ETH Zurich.

Structural Biology and Mechanism of Inhibition

High-resolution structures of PDE catalytic domains determined by crystallography and cryo-electron microscopy were produced by teams at Lawrence Berkeley National Laboratory, Max Planck Institute for Biophysical Chemistry, Diamond Light Source, and collaborative networks including European Synchrotron Radiation Facility; these structures revealed active-site topology exploited by selective inhibitors developed jointly by researchers at University of Illinois Urbana-Champaign, Princeton University, Northwestern University, and industry partners. Structure–function studies guided lead optimization in programs run by investigators affiliated with Broad Institute, Scripps Research, Weizmann Institute of Science, and regulatory filings to U.S. Food and Drug Administration. Ongoing structural efforts link academic consortia at California Institute of Technology and University of Geneva with translational initiatives supported by Bill & Melinda Gates Foundation and philanthropic research funds.

Category:Enzymes